Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Bioelectrical impedance analysis for monitoring cancer patients receiving chemotherapy and home parenteral nutrition

Fig. 3

a Log rank test Survival curve for PG-SGA at T2. PG-SGA category A at T2 was a predictor of survival (median duration days: 652; CI 635–660; P < 0.0001); PG-SGA category C (median duration days: 162; CI 102–222) was a predictor of mortality vs. both A and B categories (P = 0.003 and P < 0.0001, respectively). The HR for PG-SGA category as a predictor of survival for category A vs. B was 0.39 (CI 0.17–0.90); for category A vs. C was 0.15 (CI 0.06–0.37), and for category B vs. C was 0.41 (CI 0.20–0.72). PG-SGA, Patient-Generated Subjective Global Assessment; Category A = well-nourished; Category B = suspected malnutrition or moderate malnutrition; Category C = severely malnourished; T2, 90 days after the start of home parenteral nutrition. b Log-rank test Survival curve for Metastasis. No metastasis (median duration days: 487; CI 88–894) vs. any metastasis (median duration days: 213; CI 163–263) was a predictor of survival (P = 0.002). The HR for no metastasis as a predictor of survival was 0.37 (CI 0.21–0.63)

Back to article page